Compare JPMorgan Equity Premium Income ETF (JEPI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Zimmer Biomet Holdings Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 2.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| JEPI | ZBH | |
|---|---|---|
Market Cap | $45.55B | $16.95B |
Volume | 3,820,809 | 2,505,240 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $103.98 |
52-Week Low | $55.29 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.67, up 0.39% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend distributions with recent payments of $0.37 in August and July 2026. Media coverage focuses on income strategies and tax implications, with Seeking Alpha highlighting JEPI's role as a hedge against tech-led market declines.
The outlook remains income-focused with steady monthly distributions, though covered-call strategies may limit upside during rallies. Key risks include interest rate sensitivity and tax inefficiencies, while institutional interest continues with Envestnet increasing its stake by 20.9% in Q2 2026.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
